| Year |
Citation |
Score |
| 2019 |
Marek GJ, Cunningham KA, Rasmussen K. Translating Pharmacology into Therapeutics to Fight the Opioid Crisis. The Journal of Pharmacology and Experimental Therapeutics. 371: 394-395. PMID 31628259 DOI: 10.1124/Jpet.119.262477 |
0.572 |
|
| 2018 |
Balcer OM, Seager MA, Gleason SD, Li X, Rasmussen K, Maxwell JK, Nomikos G, Degroot A, Witkin JM. Evaluation of 5-HT receptor antagonism for the treatment of anxiety, depression, and schizophrenia through the use of receptor-deficient mice. Behavioural Brain Research. 360: 270-278. PMID 30543903 DOI: 10.1016/J.Bbr.2018.12.019 |
0.7 |
|
| 2017 |
Witkin JM, Mitchell S, Wafford K, Carter G, Gilmour G, Li J, Eastwood B, Overshiner C, Li X, Rorick-Kehn L, Rasmussen K, Anderson W, Nikolayev A, Tolstikov V, Kuo MS, et al. Comparative Effects of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist, and Ketamine, a Non-Competitive NMDA Receptor Antagonist, in Rodents: Evidence Supporting Use for the Treatment of Depression. The Journal of Pharmacology and Experimental Therapeutics. PMID 28138040 DOI: 10.1124/Jpet.116.238121 |
0.44 |
|
| 2016 |
Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, ... ... Rasmussen K, et al. Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism. Nature Medicine. PMID 27820603 DOI: 10.1038/Nm.4221 |
0.354 |
|
| 2016 |
Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner CD, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM. The Rapidly-Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. The Journal of Pharmacology and Experimental Therapeutics. PMID 27189960 DOI: 10.1124/Jpet.116.233627 |
0.449 |
|
| 2012 |
Fell MJ, Katner JS, Rasmussen K, Nikolayev A, Kuo MS, Nelson DL, Perry KW, Svensson KA. Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade. Frontiers in Psychiatry. 3: 49. PMID 22629251 DOI: 10.3389/Fpsyt.2012.00049 |
0.407 |
|
| 2011 |
Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, et al. N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. The Journal of Pharmacology and Experimental Therapeutics. 336: 165-77. PMID 20947638 DOI: 10.1124/Jpet.110.172957 |
0.659 |
|
| 2009 |
Gehlert DR, Rasmussen K, Shaw J, Li X, Ardayfio P, Craft L, Coskun T, Zhang HY, Chen Y, Witkin JM. Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. The Journal of Pharmacology and Experimental Therapeutics. 329: 429-38. PMID 19182070 DOI: 10.1124/Jpet.108.143362 |
0.369 |
|
| 2007 |
Rasmussen K, Hsu MA, Noone S, Johnson BG, Thompson LK, Hemrick-Luecke SK. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms. Schizophrenia Bulletin. 33: 1291-7. PMID 17660489 DOI: 10.1093/Schbul/Sbm087 |
0.416 |
|
| 2007 |
Rasmussen K, Hsu MA, Yang Y. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 786-92. PMID 17063151 DOI: 10.1038/Sj.Npp.1301239 |
0.409 |
|
| 2006 |
Verma V, Rasmussen K, Dawe GS. Effects of short-term and chronic olanzapine treatment on immediate early gene protein and tyrosine hydroxylase immunoreactivity in the rat locus coeruleus and medial prefrontal cortex. Neuroscience. 143: 573-85. PMID 16979829 DOI: 10.1016/J.Neuroscience.2006.08.010 |
0.565 |
|
| 2006 |
Takeuchi K, Kohn TJ, Honigschmidt NA, Rocco VP, Spinazze PG, Hemrick-Luecke SK, Thompson LK, Evans DC, Rasmussen K, Koger D, Lodge D, Martin LJ, Shaw J, Threlkeld PG, Wong DT. Advances toward new antidepressants beyond SSRIs: 1-aryloxy-3-piperidinylpropan-2-ols with dual 5-HT1A receptor antagonism/SSRI activities. Part 5. Bioorganic & Medicinal Chemistry Letters. 16: 2347-51. PMID 16298130 DOI: 10.1016/j.bmcl.2005.11.007 |
0.312 |
|
| 2005 |
Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. The Journal of Pharmacology and Experimental Therapeutics. 315: 1265-77. PMID 16141369 DOI: 10.1124/Jpet.105.089326 |
0.45 |
|
| 2005 |
Seager MA, Barth VN, Phebus LA, Rasmussen K. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology. 181: 126-33. PMID 15719213 DOI: 10.1007/S00213-005-2198-2 |
0.712 |
|
| 2005 |
Rasmussen K, Martin H, Berger JE, Seager MA. The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats. Neuropharmacology. 48: 173-80. PMID 15695156 DOI: 10.1016/J.Neuropharm.2004.09.010 |
0.718 |
|
| 2004 |
Seager MA, Huff KD, Barth VN, Phebus LA, Rasmussen K. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biological Psychiatry. 55: 1103-9. PMID 15158430 DOI: 10.1016/J.Biopsych.2004.02.012 |
0.72 |
|
| 2004 |
Rasmussen K, Hsu MA, Vandergriff J. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons. Neuropharmacology. 46: 620-8. PMID 14996539 DOI: 10.1016/J.Neuropharm.2003.11.013 |
0.44 |
|
| 2004 |
Rasmussen K, McCreary AC, Shanks EA. Attenuation of the effects of fluoxetine on serotonergic neuronal activity by pindolol in rats. Neuroscience Letters. 355: 1-4. PMID 14729220 DOI: 10.1016/J.Neulet.2003.10.039 |
0.441 |
|
| 2003 |
Gronier BS, Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neuroscience Letters. 349: 196-200. PMID 12951202 DOI: 10.1016/S0304-3940(03)00851-6 |
0.415 |
|
| 2003 |
Rasmussen K, Vandergriff J. The selective iGluR1-4 (AMPA) antagonist LY300168 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioural signs of morphine withdrawal. Neuropharmacology. 44: 88-92. PMID 12559125 DOI: 10.1016/S0028-3908(02)00296-4 |
0.451 |
|
| 2001 |
Dawe GS, Huff KD, Vandergriff JL, Sharp T, O'Neill MJ, Rasmussen K. Olanzapine activates the rat locus coeruleus: in vivo electrophysiology and c-Fos immunoreactivity. Biological Psychiatry. 50: 510-20. PMID 11600104 DOI: 10.1016/S0006-3223(01)01171-4 |
0.649 |
|
| 2000 |
Czachura JF, Rasmussen K. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat Naunyn-Schmiedeberg's Archives of Pharmacology. 362: 266-275. PMID 10997729 DOI: 10.1007/S002100000290 |
0.462 |
|
| 2000 |
Rasmussen K, Calligaro DO, Czachura JF, Dreshfield-Ahmad LJ, Evans DC, Hemrick-Luecke SK, Kallman MJ, Kendrick WT, Leander JD, Nelson DL, Overshiner CD, Wainscott DB, Wolff MC, Wong DT, Branchek TA, et al. The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. The Journal of Pharmacology and Experimental Therapeutics. 294: 688-700. PMID 10900249 |
0.326 |
|
| 2000 |
Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophrenia Research. 42: 249-59. PMID 10785583 DOI: 10.1016/S0920-9964(99)00138-3 |
0.417 |
|
| 2000 |
Gronier B, Perry KW, Rasmussen K. Activation of the mesocorticolimbic dopaminergic system by stimulation of muscarinic cholinergic receptors in the ventral tegmental area Psychopharmacology. 147: 347-355. PMID 10672627 DOI: 10.1007/S002130050002 |
0.365 |
|
| 2000 |
Fink-Jensen A, Rasmussen T, Shannon H, Calligaro D, Delapp N, Rasmussen K, Ward J, Sheardown M, Jeppesen L, Sauerberg P, Bymaster F. The selective muscarinic receptor agonist PTAC exhibits functional dopamine antagonism and decreases scopolamine-induced hyperactivity in rodents. Role of tegmental cholinergic neurons Schizophrenia Research. 41: 240. DOI: 10.1016/S0920-9964(00)90903-4 |
0.413 |
|
| 1999 |
Vandergriff J, Rasmussen K. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal Neuropharmacology. 38: 217-222. PMID 10218862 DOI: 10.1016/S0028-3908(98)00196-8 |
0.441 |
|
| 1999 |
Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: a basic science update. The British Journal of Psychiatry. Supplement. 36-40. PMID 10211140 DOI: 10.1192/S0007125000293653 |
0.418 |
|
| 1999 |
Bymaster FP, Shannon HE, Rasmussen K, DeLapp NW, Ward JS, Calligaro DO, Mitch CH, Whitesitt C, Ludvigsen TS, Sheardown M, Swedberg M, Rasmussen T, Olesen PH, Jeppesen L, Sauerberg P, et al. Potential role of muscarinic receptors in schizophrenia. Life Sciences. 64: 527-34. PMID 10069519 DOI: 10.1016/S0024-3205(98)00597-9 |
0.416 |
|
| 1999 |
Carlezon WA, Rasmussen K, Nestler EJ. AMPA antagonist LY293558 blocks the development, without blocking the expression, of behavioral sensitization to morphine. Synapse (New York, N.Y.). 31: 256-62. PMID 10051106 DOI: 10.1002/(Sici)1098-2396(19990315)31:4<256::Aid-Syn3>3.0.Co;2-E |
0.378 |
|
| 1999 |
Shannon HE, Bymaster FP, Rasmussen K, DeLapp NW, Calligaro DO, Perry KW, Mitch CH, Ward JS, Fink-Jensen A, Olesen P, Rasmussen T, Sheardown M, Swedberg M, Jeppesen L, Sauerberg P. Behavioral and electrophysiological effects of the antipsychotic-like muscarinic agonist PTAC Life Sciences. 64: 587. DOI: 10.1016/S0024-3205(99)90529-5 |
0.347 |
|
| 1999 |
Bymaster FP, Shannon HE, DeLapp NW, Calligaro DO, Perry KW, Zhang W, Rasmussen K, Ward JS, Fink-Jensen A, Olesen P, Rasmussen T, Sheardown M, Swedberg M, Jeppesen L, Sauerberg P. Muscarinic receptor characterization and neurochemical effects of the antipsychotic-like muscarinic agonist PTAC Life Sciences. 64: 579. DOI: 10.1016/S0024-3205(99)90514-3 |
0.378 |
|
| 1998 |
Bymaster FP, Shannon HE, Rasmussen K, Delapp NW, Mitch CH, Ward JS, Calligaro DO, Ludvigsen TS, Sheardown MJ, Olesen PH, Swedberg MD, Sauerberg P, Fink-Jensen A. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane . European Journal of Pharmacology. 356: 109-19. PMID 9774240 DOI: 10.1016/S0014-2999(98)00487-7 |
0.385 |
|
| 1998 |
Gronier B, Rasmussen K. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: An in vivo electrophysiological study in the rat British Journal of Pharmacology. 124: 455-464. PMID 9647468 DOI: 10.1038/sj.bjp.0701850 |
0.336 |
|
| 1997 |
Rasmussen K, Czachura JF. Nicotine withdrawal leads to increased sensitivity of serotonergic neurons to the 5-HT(1A), agonist 8-OH-DPAT Psychopharmacology. 133: 343-346. PMID 9372532 DOI: 10.1007/S002130050411 |
0.414 |
|
| 1997 |
Rasmussen K, Kallman MJ, Helton DR. Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response Synapse. 27: 145-152. PMID 9266775 DOI: 10.1002/(Sici)1098-2396(199710)27:2<145::Aid-Syn5>3.0.Co;2-E |
0.378 |
|
| 1997 |
Rasmussen K, Gates MR, Burger JE, Czachura JF. The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition. Neuroscience Letters. 222: 61-4. PMID 9121724 DOI: 10.1016/S0304-3940(97)13346-8 |
0.36 |
|
| 1997 |
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Archives of Neurology. 54: 465-73. PMID 9109749 DOI: 10.1001/Archneur.1997.00550160091022 |
0.31 |
|
| 1997 |
Rasmussen K, Czachura J, Stockton M. Electrophysiological studies of the effects of CCK antagonists on dopamine neurons Biological Psychiatry. 42: 288S. DOI: 10.1016/S0006-3223(97)88099-7 |
0.377 |
|
| 1996 |
Stockton ME, Rasmussen K. Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells Psychopharmacology. 124: 50-56. PMID 8935800 DOI: 10.1007/Bf02245605 |
0.321 |
|
| 1996 |
Rasmussen K, Kendrick WT, Kogan JH, Aghajanian GK. A selective AMPA antagonist, LY293558, suppresses morphine withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 15: 497-505. PMID 8914123 DOI: 10.1016/S0893-133X(96)00094-2 |
0.614 |
|
| 1996 |
Helton DR, Berger JE, Czachura JF, Rasmussen K, Kallman MJ. Central nervous system characterization of the new cholecystokininB antagonist LY288513 Pharmacology Biochemistry and Behavior. 53: 493-502. PMID 8866946 DOI: 10.1016/0091-3057(95)02122-1 |
0.439 |
|
| 1996 |
Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons Neuropsychopharmacology. 14: 97-104. PMID 8822532 DOI: 10.1016/0893-133X(94)00130-R |
0.341 |
|
| 1996 |
Rasmussen K, Czachura JF, Kallman MJ, Helton DR. The CCK-B antagonist LY288513 blocks the affects of nicotine withdrawal on auditory startle Neuroreport. 7: 1050-1052. PMID 8804049 DOI: 10.1097/00001756-199604100-00019 |
0.344 |
|
| 1996 |
Krystal JH, Compere S, Nestler EJ, Rasmussen K. Nimodipine reduction of naltrexone-precipitated locus coeruleus activation and abstinence behavior in morphine-dependent rats. Physiology & Behavior. 59: 863-6. PMID 8778878 DOI: 10.1016/0031-9384(95)02206-6 |
0.403 |
|
| 1995 |
Rasmussen K. The role of the locus coeruleus and N-methyl-D-aspartic acid (NMDA) and AMPA receptors in opiate withdrawal Neuropsychopharmacology. 13: 295-300. PMID 8747753 DOI: 10.1016/0893-133X(95)00082-O |
0.386 |
|
| 1995 |
Rasmussen K, Czachura JF. Nicotine withdrawal leads to increased firing rates of midbrain dopamine neurons Neuroreport. 7: 329-332. PMID 8742482 DOI: 10.1097/00001756-199512000-00079 |
0.348 |
|
| 1995 |
Rasmussen K, Brodsky M, Inturrisi CE. NMDA antagonists and clonidine block c-fos expression during morphine withdrawal Synapse. 20: 68-74. PMID 7624831 DOI: 10.1002/Syn.890200110 |
0.377 |
|
| 1995 |
Rasmussen K, Rocco VP. Chapter 1. Recent Progress in Serotonin (5-HT)1A Receptor Modulators Annual Reports in Medicinal Chemistry. 30: 1-9. DOI: 10.1016/S0065-7743(08)60914-8 |
0.372 |
|
| 1994 |
Rasmussen K, Helton DR, Berger JE, Scearce E. The CCK-B antagonist LY288513 blocks diazepam-withdrawal-induced increases in auditory startle response Annals of the New York Academy of Sciences. 713: 374-376. PMID 8185192 DOI: 10.1111/J.1749-6632.1994.Tb44097.X |
0.318 |
|
| 1994 |
Rasmussen K. CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain dopamine neurons Annals of the New York Academy of Sciences. 713: 300-311. PMID 8185172 DOI: 10.1111/J.1749-6632.1994.Tb44078.X |
0.351 |
|
| 1994 |
Rasmussen K, Yu MJ, Czachura JF. Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity Synapse. 17: 278-282. PMID 7992203 DOI: 10.1002/Syn.890170409 |
0.312 |
|
| 1994 |
Foreman MM, Fuller RW, Rasmussen K, Nelson DL, Calligaro DO, Zhang L, Barrett JE, Booher RN, Paget CJ, Flaugh ME. Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity. The Journal of Pharmacology and Experimental Therapeutics. 270: 1270-81. PMID 7523657 |
0.323 |
|
| 1993 |
Rasmussen K, Howbert JJ, Stockton ME. Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691: Mediation through feedback pathways from forebrain sites Synapse. 15: 95-103. PMID 8259526 DOI: 10.1002/Syn.890150202 |
0.308 |
|
| 1993 |
Rasmussen K, Berger JE, Helton DR, Scearce E. The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle Neuroreport. 5: 154-156. PMID 8111002 DOI: 10.1097/00001756-199311180-00015 |
0.369 |
|
| 1992 |
Melia KR, Rasmussen K, Terwilliger RZ, Haycock JW, Nestler EJ, Duman RS. Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments. Journal of Neurochemistry. 58: 494-502. PMID 1345939 DOI: 10.1111/J.1471-4159.1992.Tb09748.X |
0.341 |
|
| 1991 |
Rasmussen K. Afferent effects on locus coeruleus in opiate withdrawal Progress in Brain Research. 88: 207-216. PMID 1839935 |
0.314 |
|
| 1991 |
Rasmussen K, Fuller RW, Stockton ME, Perry KW, Swinford RM, Ornstein PL. NMDA receptor antagonists suppress behaviors but not norepinephrine turnover or locus coeruleus unit activity induced by opiate withdrawal. European Journal of Pharmacology. 197: 9-16. PMID 1832640 DOI: 10.1016/0014-2999(91)90358-W |
0.42 |
|
| 1991 |
Rasmussen K, Stockton ME, Czachura JF. The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons European Journal of Pharmacology. 205: 113-116. PMID 1811993 DOI: 10.1016/0014-2999(91)90781-K |
0.441 |
|
| 1991 |
Rasmussen K, Krystal JH, Aghajanian GK. Excitatory amino acids and morphine withdrawal: differential effects of central and peripheral kynurenic acid administration. Psychopharmacology. 105: 508-12. PMID 1771218 DOI: 10.1007/Bf02244371 |
0.541 |
|
| 1991 |
Rasmussen K, Stockton ME, Czachura JF, Jeffry Howbert J. Cholecystokinin (CCK) and schizophrenia: the selective CCKB antagonist LY262691 decreases midbrain dopamine unit activity European Journal of Pharmacology. 209: 135-138. PMID 1687681 DOI: 10.1016/0014-2999(91)90025-L |
0.397 |
|
| 1990 |
Rasmussen K, Aghajanian GK. Serotonin excitation of facial motoneurons: receptor subtype characterization. Synapse (New York, N.Y.). 5: 324-32. PMID 2360199 DOI: 10.1002/Syn.890050409 |
0.548 |
|
| 1990 |
Aghajanian GK, Sprouse JS, Sheldon P, Rasmussen K. Electrophysiology of the central serotonin system: receptor subtypes and transducer mechanisms. Annals of the New York Academy of Sciences. 600: 93-103; discussion 1. PMID 2123618 DOI: 10.1111/J.1749-6632.1990.Tb16875.X |
0.549 |
|
| 1990 |
Rasmussen K, Beitner-Johnson DB, Krystal JH, Aghajanian GK, Nestler EJ. Opiate withdrawal and the rat locus coeruleus: behavioral, electrophysiological, and biochemical correlates. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 10: 2308-17. PMID 2115910 DOI: 10.1523/Jneurosci.10-07-02308.1990 |
0.58 |
|
| 1989 |
Rasmussen K, Aghajanian GK. Failure to block responses of locus coeruleus neurons to somatosensory stimuli by destruction of two major afferent nuclei. Synapse (New York, N.Y.). 4: 162-4. PMID 2781467 DOI: 10.1002/Syn.890040210 |
0.51 |
|
| 1989 |
Aghajanian GK, Rasmussen K. Intracellular studies in the facial nucleus illustrating a simple new method for obtaining viable motoneurons in adult rat brain slices. Synapse (New York, N.Y.). 3: 331-8. PMID 2740992 DOI: 10.1002/Syn.890030406 |
0.495 |
|
| 1989 |
Rasmussen K, Aghajanian GK. Withdrawal-induced activation of locus coeruleus neurons in opiate-dependent rats: attenuation by lesions of the nucleus paragigantocellularis. Brain Research. 505: 346-50. PMID 2598056 DOI: 10.1016/0006-8993(89)91466-2 |
0.577 |
|
| 1988 |
Rasmussen K, Aghajanian GK. Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 1: 101-7. PMID 2908015 DOI: 10.1016/0893-133X(88)90001-2 |
0.595 |
|
| 1987 |
Wilkinson LO, Abercrombie ED, Rasmussen K, Jacobs BL. Effect of buspirone on single unit activity in locus coeruleus and dorsal raphe nucleus in behaving cats. European Journal of Pharmacology. 136: 123-7. PMID 3595712 DOI: 10.1016/0014-2999(87)90789-8 |
0.321 |
|
| 1986 |
Rasmussen K, Glennon RA, Aghajanian GK. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity. European Journal of Pharmacology. 132: 79-82. PMID 3816969 DOI: 10.1016/0014-2999(86)90014-2 |
0.547 |
|
| 1986 |
Rasmussen K, Aghajanian GK. Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Research. 385: 395-400. PMID 3096493 DOI: 10.1016/0006-8993(86)91090-5 |
0.613 |
|
| 1984 |
Heym J, Rasmussen K, Jacobs BL. Some behavioral effects of hallucinogens are mediated by a postsynaptic serotonergic action: evidence from single unit studies in freely moving cats. European Journal of Pharmacology. 101: 57-68. PMID 6745319 DOI: 10.1016/0014-2999(84)90030-X |
0.321 |
|
| Show low-probability matches. |